Capricor Therapeutics CAPR Return on equity

Return on equity at other companies

PfizerPFE

10.6%—

Sarepta Therapeutics, Inc.SRPT

-9.3%+2,662pp

Celldex TherapeuticsCLDX

-43.9%+70.0pp

Dyne Therapeutics, Inc.DYN

-58.9%-4.4pp

Edgewise Therapeutics, Inc.EWTX

-38.1%+13.4pp

Sutro BiopharmaSTRO

-234.2%—

FAQ

What is Capricor Therapeutics's return on equity?

Capricor Therapeutics (CAPR) reported return on equity of -56.4% in Q1 2026.

How has Capricor Therapeutics's return on equity changed year-over-year?

Capricor Therapeutics's return on equity increased by 25.2% year-over-year, from -75.4% to -56.4%.

What is the long-term trend for Capricor Therapeutics's return on equity?

Over 5 years (2020 to 2025), Capricor Therapeutics's return on equity has grown at a -9.8% compound annual growth rate (CAGR), from -78% to -46.6%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.